Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of α2A-adrenoceptors: A dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 305, Issue 1, 2003, Pages 338-346

  Gobert, A ^a   Di Cara, B ^a   Cistarelli, L ^a   Millan, M J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 2,3,9,13B TETRAHYDRO 1,2 DIMETHYL 1H IMIDAZO[3,4 F]MORPHANTHRIDINE; ACETYLCHOLINE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2A ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIPARKINSON AGENT; ATIPAMEZOLE; BRIMONIDINE; CHOLINESTERASE INHIBITOR; GUANABENZ; PIRIBEDIL; QUINEROLANE; TALIPEXOLE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ADRENERGIC RECEPTOR BLOCKING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC TRANSMISSION; COGNITION; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DYSKINESIA; FRONTAL CORTEX; HIPPOCAMPUS; INHIBITION KINETICS; LIGAND BINDING; MALE; MOVEMENT (PHYSIOLOGY); NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ADRENERGIC ANTAGONISTS; ANIMALS; AZEPINES; CHOLINESTERASE INHIBITORS; DIALYSIS; DOPAMINE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIPPOCAMPUS; IDAZOXAN; PIRIBEDIL; PREFRONTAL CORTEX; QUINOLINES; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0037382089     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.046383     Document Type: Article

References (60)

1. Acquas E, Wilson C, and Fibiger HC (1998) Pharmacology of sensory stimulationevoked increases in frontal cortical acetylcholine release. Neuroscience 85:73-83.
2. Amassiri-Teule M, Amoroso D, Forloni GL, Rossi-Arnaud C, and Consolo S (1993) Mechanical deafferentation of basal forebrain-cortical pathways and neurotoxic lesions of the nucleus basalis magnocellularis: comparative effect on spatial learning and cortical acetylcholine release in vivo. Behav Brain Res 54:145-152.
3. Bergman J and Lerner V (2002) Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 25:107-110.
4. Bertorelli R, Forloni G, and Consolo S (1991) Modulation of cortical in vivo acetylcholine release by the basal nuclear complex: role of the pontomesencephalic tegmental area. Brain Res 563:353-356.
5. Bezard E, Brotchie JM, and Gross CE (2001) Pathophysiology of levo-dopa induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588.
6. Bing G, Zhang YI, Watanabe Y, McEwen BS, and Stone EA (1994) Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res 668:261-265.
7. 2-Adrenoceptor antagonists: a new approach to Parkinson's disease? CNS Drugs 10:189-207.
8. Broersen LM, Heinsbroek RPW, de Bruin JPC, Uylings HBM, and Olivier B (1995) The role of the medial prefrontal cortex of rats in short-term memory functioning: further support for involvement of cholinergic, rather than dopaminergic, mechanisms. Brain Res 674:221-229.
9. 2C-, inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 109:819-826.
10. 2-adrenoceptor antagonist, on memory performance is young adult and aged rodents. J Pharmacol Exp Ther 301:187-196.
11. Cuadra G and Giacobini E (1995) Effects of cholinesterase inhibitors and clonidine coadministration on rat cortex neurotransmitters in vivo. J Pharmacol Exp Ther 275:228-236.
12. Day J and Fibiger HC (1993) Dopaminergic regulation of cortical acetylcholine release: effects of dopamine receptor agonists. Neuroscience 54:643-648.
13. 2 dopamine receptor subtypes. J Pharmacol Exp Ther 277:775-783.
14. Descarries L and Umbriaco D (1995) Ultrastructural basis of monoamine and acetylcholine function in CNS. The Neurosciences 7:309-318.
15. Di Chiara G, Morelli M, and Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:228-233.
16. Dubois B, Danzé F, Pillon B, Cusimano G, Lhermitte F, and Agid Y (1986) Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 22:26-30.
17. Giovannini MG, Rakovska A, Benton RS, Pazzagli M, Bianchi L, and Pepeu G (2001) Effects of novelty and habituation of acetylcholine GABA and glutamate release from the frontal cortex and hippocampus of freely moving rats. Neurosciences 196:43-53.
18. Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L, and Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and hetero-receptor mediated control of release. Neuroscience 84:413-429.
19. Hajszan T and Zaborszky L (2002) Direct catecholaminergic-cholinergic interactions in the basal forebrain. III. Adrenergic innervation of choline acetyltransferasecontaining neurons in the rat. J Comp Neurol 449:141-157.
20. Hironaka N, Tanaka KI, Izaki Y, Hori K, and Nomura M (2001) Memory-related acetylcholine efflux from rat prefrontal cortex and hippocampus: a microdialysis study. Brain Res 901:143-150.
21. Hurtig HI (1997) Problems with current pharmacologic treatment of Parkinson's disease. Exp Neurol 144:10-16.
22. Ichikawa J, Dai J, and Meltzer HY (2000) Acetylcholinesterase inhibitors are neither necessary nor desirable for microdialysis studies of brain acetylcholine. Curr Separations 19:37-44.
23. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, and Meltzer HY (2002) Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26:325-339.
24. Jenner P (1995) The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 45:S6-S12.
25. Jenner P (2000) Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol 247:43-50.
26. 2-adrenergic receptors. J Pharmacol Exp Ther 293:1-7.
27. Li R, Nishijo H, Wang Q, Uwano T, Tamura R, Ohtani O, and Ono T (2001) Light and electron microscopic study of cholinergic and noradrenergic elements in the basolateral nucleus of the rat amygdala: evidence for interactions between the two systems. J Comp Neurol 439:411-425.
28. Liu JK and Kato T (1994) Effect of physostigmine on relative acetylcholine output induced by systemic treatment with scopolamine in vivo microdialysis of rat frontal cortex. Neurochem Int 24:589-596.
29. Maurin B, Baunez C, Bonhomme C, Chezaubernard C, Nieoullon A, and Amalric M (2001) Cognitive deficits in 6-OHDA lesioned rats are improved by chronic treatment with the dopamine agonist, piribedil. Behav Pharmacol 12:S63.
30. 2-adrenoceptor antagonists idazoxan and yohimbine can unmask the postsynaptic dopamine agonist effects of B-HT920. Eur J Pharmacol 170:105-107.
31. 2A-ARs in the control of nociception, motor behaviour and hippocampal synthesis of noradrenaline. J Pharmacol Exp Ther 270:958-972.
32. 2-adrenoceptors: a cellular and functional characterization. J Pharmacol Exp Ther 297:1-12.
33. Millan MJ, Lejeune F, and Gobert A (2000) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14:114-138.
34. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned, human receptor subtypes. J Pharmacol Exp Ther 303:791-804.
35. Moroni F, Tanganelli S, Antonelli T, Carla V, Bianchi C, and Beani L (1983) Modulation of cortical acetylcholine and γ-aminobutyric acid release in freely moving guinea pigs: effects of clonidine and other adrenergic drugs. J Pharmacol Exp Ther 277:435-440.
36. Nagaraja D and Jayashree S (2001) Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment. Am J Psychiatry 158:1517-1519.
37. 2-adrenoceptor. J Pharmacol Exp Ther 303:805-814.
38. 2" receptor subtypes. J Pharmacol Exp Ther 303:815-822.
39. 2-antagonist, can reduce scopolamine-induced hyperactivity in rats. Behav Pharmacol 8:465-470.
40. Perry E, Walker M, Grace J, and Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22:273-280.
41. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, and Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 18:1484-1491.
42. Reading PJ, Luce AK, and McKeith IG (2001) Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16:1171-1195.
43. 2-adrenergic subtypes. J Pharmacol Exp Ther 270:946-957.
44. 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol 372:135-165.
45. Sandyk R and Iacono RP (1990) Early versus late-onset Parkinson's disease: the role of the locus coeruleus. Int J Neurosci 52:243-247.
46. Sarter M and Bruno JP (1998) Cortical acetylcholine, reality distortion, schizophrenia and Lewy body dementia: too much or too little cortical acetylcholine. Brain Cognit 38:297-316.
47. Sarter M and Bruno JP (2000) Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 95:933-952.
48. Shirazi-Southall S, Rodrigez DE, and Nomikos GG (2002) Effects of typical and atypical antipsychotics and receptor selective compounds on acetylcholine efflux in the hippocampus of the rat. Neuropsychopharmacology 26:583-594.
49. Singer C (2002) Adverse effects in the treatment of Parkinson's disease. Expert Rev Neurotherapeutics 2:105-118.
50. Smiley JF, Subramanian M, and Mesulam MM (1999) Monoaminergic-cholinergic interactions in the primate basal forebrain. Neuroscience 93:817-829.
51. Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, and Jenner P (2002) Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Mov Disord 17:887-901.
52. 2A-adrenergic receptor like immunoreactivity in the rat central nervous system. J Comp Neural 372:111-134.
53. 2-adrenoceptor agonists and antagonists. J Neurochem 68:778-785.
54. Toide K and Arima T (1989) Effects of cholinergic drugs on extracellular levels of acetylcholine and choline in rat cortex, hippocampus and striatum studied by brain dialysis. Eur J Pharmacol 173:133-141.
55. 2 long receptor-deficient mice display alterations in striatumdependent functions. J Neurosci 20:8305-8314.
56. Williams JA and Reiner PB (1993) Noradrenaline hyperpolarizes identified rat mesopontine cholinergic neurons in vitro. J Neurosci 13:3878-3883.
57. Wilms H, Sievers J, and Deuschl G (1999) Animal models of tremor. Mov Disord 14:557-571.
58. 2B-adrenoceptor subtypes. Eur J Pharmacol 168:381-386.
59. 2A adrenergic receptors are present in basal forebrain cholinergic projection neurons. Soc Neurosci Abstr 21:69.
60. Zhang W, Basile AS, Gomeza J, Volpicelli J, Volpicelli LA, Levey AI, and Wess J (2002) Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J Neurosci 22:1709-1717.